Technological Advancements Driving 8.9% CAGR Growth in the Molecular Diagnostics Market

Molecular diagnostics market was valued at $19.2 billion in 2025 and is projected to reach $48.0 billion by 2035, growing at a CAGR of 8.9% during the forecast period (2026-2035). The molecular diagnostics market is expanding due to the growing prevalence of infectious and chronic diseases, rising demand for early diagnosis, and increasing adoption of personalized and point-of-care testing. But technological advancement is the key growth driver, with innovations in PCR, liquid biopsy, next-generation sequencing, and AI, it is significantly enhancing diagnostic accuracy, speed, and clinical value.

Browse the full report description of “Molecular Diagnostics Market Size, Share & Trends Analysis Report by Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), DNA Microarray, Next-Generation Sequencing (NGS), Isothermal Nucleic Acid Amplification, and Other Technologies), By Product(Testing Equipment, Diagnostic Reagents & Kits, and Services & Software), By Applications (Infectious Diseases, Cancer, Cardiovascular Disease (CVD), Genetic Testing, Neurological Disease, and Other), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/molecular-diagnostics-market

Technological Innovations Driving Accuracy and Efficiency in Molecular Diagnostics

Polymerase Chain Reaction (PCR) remains central to molecular diagnostics due to its high sensitivity and specificity for detecting nucleic acids. Among PCR technologies, real-time PCR and multiplex PCR assays allow the detection of multiple pathogens or genetic markers from a single sample, significantly enhancing test throughput and efficiency, particularly in infectious disease and cancer diagnostics.

Integration of artificial intelligence (AI) and predictive analytics in liquid biopsy is transforming the molecular diagnostics landscape. AI models can track ctDNA mutations across multiple time points to identify early signs of tumor progression or recurrence before they are visible on imaging scans. And this capability is allowing oncologists to adjust therapy proactively, potentially improving survival outcomes. Along with this, now AI tools can spot new mutations that make cancer medicines less effective, helping doctors change treatments sooner. For example, in lung cancer, AI can detect resistance mutations weeks before they appear on scans

Apart from this, AI and deep learning models are reducing genomic noise by distinguishing true tumor-derived mutations from background mutations or sequencing errors. This is improving the accuracy and reliability of liquid biopsy results.

Molecular Diagnostics Market: Recent Strategic Collaborations and Expansions

• In April 2025, Cepheid (part of Danaher) and Oxford Nanopore Technologies announced a strategic collaboration to develop and commercialize an integrated sequencing workflow that combines Cepheid’s GeneXpert system with Oxford Nanopore’s rapid sequencing platform. This aims to deliver automated, fast, and information-rich sequencing workflows for infectious disease analysis in molecular diagnostics.

• In August 2025, Abbott announced an investment in expanding into molecular blood and plasma screening with its Alinity n system, capable of detecting DNA and RNA from multiple pathogens. This marks a strategic move into nucleic acid-based testing for blood safety and infectious pathogen screening.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Technology
• Product
• Application

• Competitive Landscape – Abbott Laboratories, Danaher Corp. (Cepheid), F.Hoffmann La Roche Ltd. (Roche Diagnostics), QIAGEN N.V. and Thermo Fisher Scientific, Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Molecular Diagnostics Market Report Segment

By Technology

• Polymerase Chain Reaction (PCR)
• In Situ Hybridization (ISH)
• DNA Microarray
• Next-Generation Sequencing (NGS)
• Isothermal Nucleic Acid Amplification
• Other Technologies

By Product

• Testing Instruments
• Diagnostic Reagents and Kits
• Services & Software

By Application

• Infectious Disorders (including COVID-19)
• Cancer
• Cardiovascular Disease (CVD)
• Genetic Testing
• Neurological Disease
• Other

Global Molecular Diagnostics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/molecular-diagnostics-market